Abstract
A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 269-274 |
Number of pages | 6 |
Journal | Investigational New Drugs |
Volume | 4 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1986 |
Keywords
- esorubicin
- phase II
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)